Suppr超能文献

基于病理生理机制的糖尿病肾病中医综合治疗研究

Research on TCM Comprehensive Treatment of DKD Based on Pathophysiological Mechanism.

作者信息

Piao Lei, Ma Jian, Zhao Na, Hou Yongqing, Wang Tehasi

机构信息

The First Clinical Medical College, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang Province, People's Republic of China.

Endocrinology Department, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang Province, People's Republic of China.

出版信息

Diabetes Metab Syndr Obes. 2025 Jul 16;18:2369-2384. doi: 10.2147/DMSO.S523094. eCollection 2025.

Abstract

Diabetic kidney disease (DKD) is the predominant etiology of end-stage renal disease (ESRD). Despite rigorous therapeutic interventions aimed at managing hyperglycemia, regulating blood pressure, and employing renin-angiotensin system inhibitors, the incidence of DKD remains high. Recent investigations have indicated a shift in the disease spectrum of DKD accompanied by significant advancements in the development of novel therapeutic options. Nevertheless, in addition to agents such as renin-angiotensin system inhibitors (RASi), sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and mineralocorticoid receptor antagonists (MRA), there is currently no optimal strategy in contemporary medicine to effectively mitigate the progression of DKD. The application of TCM in the management of DKD has demonstrated its potential in delaying disease progression and enhancing patient quality of life, thereby playing a crucial role in the prevention and treatment of this condition. Clinical evidence supports its efficacy and safety profile. This article aimed to explore the TCM approach to DKD, focusing on aspects such as etiology, pathogenesis, syndrome differentiation, and comprehensive treatment, while also analyzing the latest research developments in the pathophysiology of DKD.

摘要

糖尿病肾病(DKD)是终末期肾病(ESRD)的主要病因。尽管采取了严格的治疗干预措施来控制血糖、调节血压并使用肾素-血管紧张素系统抑制剂,但DKD的发病率仍然很高。最近的研究表明,DKD的疾病谱发生了变化,同时新型治疗方案的开发也取得了重大进展。然而,除了肾素-血管紧张素系统抑制剂(RASi)、钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)、胰高血糖素样肽-1受体激动剂(GLP-1RA)和盐皮质激素受体拮抗剂(MRA)等药物外,当代医学目前还没有有效的策略来有效减缓DKD的进展。中医在DKD管理中的应用已显示出其在延缓疾病进展和提高患者生活质量方面的潜力,从而在该疾病的预防和治疗中发挥关键作用。临床证据支持其疗效和安全性。本文旨在探讨中医治疗DKD的方法,重点关注病因、病机、辨证论治和综合治疗等方面,同时分析DKD病理生理学的最新研究进展。

相似文献

1
基于病理生理机制的糖尿病肾病中医综合治疗研究
Diabetes Metab Syndr Obes. 2025 Jul 16;18:2369-2384. doi: 10.2147/DMSO.S523094. eCollection 2025.
2
糖尿病肾病的多学科管理:一项系统评价与荟萃分析
JBI Database System Rev Implement Rep. 2016 Jul;14(7):169-207. doi: 10.11124/JBISRIR-2016-003011.
4
结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
7
限制蛋白质摄入治疗糖尿病肾病。
Cochrane Database Syst Rev. 2023 Jan 3;1(1):CD014906. doi: 10.1002/14651858.CD014906.pub2.
8
糖尿病肾病的现状与未来方向。
J Diabetes Complications. 2022 Dec;36(12):108357. doi: 10.1016/j.jdiacomp.2022.108357. Epub 2022 Nov 14.
9
可溶性CD36在糖尿病肾病治疗中的潜在生物标志物价值:来自胰高血糖素样肽-1和胰岛素干预的证据
Front Endocrinol (Lausanne). 2025 May 27;16:1605631. doi: 10.3389/fendo.2025.1605631. eCollection 2025.
10
慢性肾脏病多种治疗时代未来肾脏保护试验的设计考量
Nephrol Dial Transplant. 2025 Feb 5;40(Supplement_1):i70-i79. doi: 10.1093/ndt/gfae210.

本文引用的文献

1
津力达颗粒通过AMPK/PGC-1α途径减轻糖尿病肾病中的足细胞凋亡和线粒体功能障碍。
Int J Mol Med. 2025 Feb;55(2). doi: 10.3892/ijmm.2024.5467. Epub 2024 Dec 13.
2
中药对糖尿病肾病肾炎症信号转导通路的调控作用及机制研究进展
Medicine (Baltimore). 2024 Sep 20;103(38):e39746. doi: 10.1097/MD.0000000000039746.
3
中药汤剂作为糖尿病肾病辅助治疗的疗效与安全性:一项随机对照试验的系统评价与Meta分析
Front Pharmacol. 2024 May 9;15:1327030. doi: 10.3389/fphar.2024.1327030. eCollection 2024.
4
中医通过靶向肠道微生物群改善糖尿病肾病。
Pharm Biol. 2024 Dec;62(1):423-435. doi: 10.1080/13880209.2024.2351946. Epub 2024 May 17.
5
用于治疗糖尿病肾病的中药:44项随机对照试验的研究水平汇总分析
Front Pharmacol. 2022 Oct 13;13:1009571. doi: 10.3389/fphar.2022.1009571. eCollection 2022.
6
肾纤维化作为糖尿病肾病的标志:靶向转化生长因子-β(TGF-β)及相关分子的潜在作用。
Expert Opin Ther Targets. 2022 Aug;26(8):721-738. doi: 10.1080/14728222.2022.2133698. Epub 2022 Oct 18.
7
中国糖尿病患病率及治疗状况 2013-2018 年
JAMA. 2021 Dec 28;326(24):2498-2506. doi: 10.1001/jama.2021.22208.
8
多酚在调节糖尿病肾病中的氧化应激、炎症、纤维化和细胞凋亡中的作用。
Endocr Metab Immune Disord Drug Targets. 2022;22(5):453-470. doi: 10.2174/1871530321666211119144309.
9
用于糖尿病肾病治疗与管理的中药的临床疗效、潜在机制及分子靶点。
Acta Pharm Sin B. 2021 Sep;11(9):2749-2767. doi: 10.1016/j.apsb.2020.12.020. Epub 2021 Feb 2.
10
糖尿病肾病的病理生理学:SGLT2 抑制剂的影响。
Nat Rev Nephrol. 2021 May;17(5):319-334. doi: 10.1038/s41581-021-00393-8. Epub 2021 Feb 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验